There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > All Other Proteins > Integrin beta 8 > Human Integrin beta 8 (ITGB8) Protein

Human Integrin beta 8 (ITGB8) Protein

This product is still under development. Please contact us if you have interest in this product. We will accelerate the development process accordingly and reserve this product for you as request.
  • Synonym
    ITGB8,Integrin beta 8
  • Source
    Human ITGB8 (IT8-H52H7) is expressed from human 293 cells (HEK293). It contains AA Glu 43 - Arg 684 (Accession # P26012-1).
    Predicted N-terminus: Glu 43
  • Molecular Characterization
    Online-Res(Glu 43 - Arg 684) P26012-1

    This protein carries a polyhistidine tag at the C-terminus.

    The protein has a calculated MW of 73.1 kDa.

  • Endotoxin
  • Formulation

    Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 150 mM NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    No activity loss was observed after storage at:

    1. 4-8°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • Background
    Integrins (ITGs) are mediators of cell-cell and cell-matrix interactions, which are also associated with embryo implantation processes by controlling the interaction of blastocyst with endometrium. During early pregnancy,Integrin beta 8 (ITGB8) has been shown to interact with latent transforming growth factor (TGF) beta 1 (TGFB1) at the fetomaternal interface. integrin beta-8 (ITGB8) when over-expressed, is correlated with the gefitinib resistance of hepatic cancer cell line HepG2/G. After ITGB8 silencing, the drug resistance is reversed as the cell proliferation decreases and apoptosis rate increases significantly by gefitinib treatment when compared to HepG2/G.
  • References
  • Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.

Comments (0)

Order Details

Price(USD) : $350.00

Price(USD) : $2310.00

Promotion & Exhibitions

  • PEGS Boston 2019
  • PepTalk 2019

Datasheet & Documentation

Contact Us

+1  800-810-0816 (US)
+86 400-682-2521 (AP)

Questions & Comments

This web search service is supported by Google Inc.